Patents by Inventor Guy Bemis

Guy Bemis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110053916
    Abstract: The present invention relates to compounds useful as inhibitors of treating tuberculosis.
    Type: Application
    Filed: August 12, 2010
    Publication date: March 3, 2011
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Tiansheng Wang, Brian Hanzelka, Ute Muh, Guy Bemis
  • Patent number: 7826979
    Abstract: Computer-based methods for modeling complex formation between a query ligand and a target macromolecule are described herein. The methods can include, for example, providing a structural model of a query ligand and a structural model of a target macromolecule; identifying a substructure of the query ligand; identifying comparison ligands in a set of 3-D structural models that each share an identical substructure with the query ligand, wherein each 3-D structural model comprises a comparison ligand and a comparison macromolecule, and wherein the comparison macromolecule has structural features homologous to the target macromolecule; mapping spatial relationships between the substructure atoms of the query ligand and the comparison ligand such that corresponding atoms are identified; assigning atomic coordinates to the corresponding atoms of the query ligand; and generating one or more output models, each model comprising a 3-D structural model of the query ligand substructure and the target macromolecule.
    Type: Grant
    Filed: February 17, 2004
    Date of Patent: November 2, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Guy Bemis, Paul Caron, Brian Hare, W. Patrick Walters
  • Patent number: 7767680
    Abstract: In general, the invention relates to novel 4-phenylpyrimidine compounds useful as ion channel modulators. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of voltage-gated sodium channels and/or calcium channels.
    Type: Grant
    Filed: November 3, 2005
    Date of Patent: August 3, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Esther Martinborough, Nicole Zimmermann, Robert B. Perni, Michael Arnost, Upul K. Bandarage, Francois Maltais, Guy Bemis
  • Publication number: 20100184753
    Abstract: In general, the invention relates to compounds useful as ion channel modulators. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of voltage-gated sodium channels and/or calcium channels.
    Type: Application
    Filed: March 15, 2010
    Publication date: July 22, 2010
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Esther Martinborough, Nicole Zimmermann, Robert B. Perni, Michael Arnost, Upul Bandarage, Francois Maltais, Guy Bemis
  • Patent number: 7716030
    Abstract: Methods of identifying potential ligands for macromolecular targets are disclosed herein. The methods comprise providing models of three dimensional structural information for ligands or a ligand:macromolecule complex, mapping spatial relationships between the models, and identifying one or more pairs of matching bonds. Databases and apparatuses are also provided.
    Type: Grant
    Filed: March 1, 2004
    Date of Patent: May 11, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Albert Pierce, Guy Bemis
  • Patent number: 7612065
    Abstract: The present invention relates to inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Grant
    Filed: March 28, 2007
    Date of Patent: November 3, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jeremy Green, Susanne Wilke, Francesco Salituro, Edmund Harrington, Jingrong Cao, Guy Bemis, Huai Gao
  • Publication number: 20090124602
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.
    Type: Application
    Filed: August 7, 2008
    Publication date: May 14, 2009
    Inventors: FRANCOIS MALTAIS, GUY BEMIS, TIANSHENG WANG, JUAN-MIGUEL JIMENEZ, RONALD KNEGTEL, CHRIS DAVIS, DAMIEN FRAYSSE
  • Publication number: 20090075981
    Abstract: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Application
    Filed: August 1, 2008
    Publication date: March 19, 2009
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Francesco Salituro, Vincent Galullo, Steven Bellon, Guy Bemis, John Cochran
  • Patent number: 7423049
    Abstract: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Grant
    Filed: May 8, 2006
    Date of Patent: September 9, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Francesco Salituro, Vincent Galullo, Steven Bellon, Guy Bemis, John Cochran
  • Publication number: 20080096901
    Abstract: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention, processes for preparing the compounds and methods of using the compositions in the treatment of various disorders.
    Type: Application
    Filed: April 13, 2007
    Publication date: April 24, 2008
    Inventors: Michael Arnost, Guy Bemis, Robert Davies, Cornelia Forster, Ronald Grey, Mark Ledeboer, Brian Ledford, Craig Marhefka, David Messersmith, Albert Pierce, Francesco Salituro, Jian Wang
  • Publication number: 20080070953
    Abstract: The present invention relates to novel classes of compounds which are inhibitors of interleukin-1? converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.
    Type: Application
    Filed: September 18, 2007
    Publication date: March 20, 2008
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Guy Bemis, Julian Golec, David Lauffer, Michael Mullican, Mark Murcko, David Livingston
  • Publication number: 20080039449
    Abstract: The present invention relates to novel classes of compounds which are inhibitors of interleukin-1? converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-?-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-?-mediated diseases and decreasing IGIF and IFN-? production using the compounds and compositions of this invention.
    Type: Application
    Filed: January 18, 2007
    Publication date: February 14, 2008
    Inventors: Mark Batchelor, David Bebbington, Guy Bemis, Wolf Fridman, Roger Gillespie, Julian Golec, David Lauffer, David Livingston, Saroop Matharu, Michael Mullican, Mark Murcko, Robert Murdoch, Robert Zelle
  • Publication number: 20080033022
    Abstract: The present invention relates to inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Application
    Filed: March 28, 2007
    Publication date: February 7, 2008
    Inventors: Francesco Salituro, Guy Bemis, Susanne Wilke, Jeremy Green, Jingrong Cao, Huai Gao, Edmund Harrington
  • Patent number: 7244735
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors of formula I: or a pharmaceutically acceptable salt thereof, wherein Ring B, Z1, Z2, U, p, Q, R1, R2, R3, and R3 are as defined herein. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including stroke, inflammatory disorders, autoimmune diseases such as SLE lupus and psoriasis, proliferative disorders such as cancer, and conditions associated with organ transplantation.
    Type: Grant
    Filed: December 2, 2004
    Date of Patent: July 17, 2007
    Assignee: Vertex Pharmaceuticals Inc.
    Inventors: Judith Straub, Michael Hale, Francois Maltais, Gabriel Martinez-Botella, Alex Aronov, Guy Bemis
  • Publication number: 20070142334
    Abstract: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to inhibitors of ZAP70. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Application
    Filed: February 5, 2007
    Publication date: June 21, 2007
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: John Cochran, Vincent Galullo, Guy Bemis
  • Publication number: 20070135466
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family and ROCK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: May 22, 2006
    Publication date: June 14, 2007
    Inventors: Mark Ledeboer, Marion Wannamaker, Luc Farmer, Tiansheng Wang, Albert Pierce, Gabriel Martinez-Botella, Randy Bethiel, Guy Bemis, Jian Wang, Francesco Salituro, Michael Arnost, Jon Come, Jeremy Green, Michelle Stewart, Craig Marhefka
  • Publication number: 20070060572
    Abstract: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Application
    Filed: May 8, 2006
    Publication date: March 15, 2007
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Francesco Salituro, Vincent Galullo, Steven Bellon, Guy Bemis, John Cochran
  • Patent number: 7169779
    Abstract: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Grant
    Filed: September 8, 2003
    Date of Patent: January 30, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Francesco Salituro, Guy Bemis, Huai Gao, Ghotas Evindar
  • Patent number: 7169798
    Abstract: The present invention provides compounds of formula I: where R1 is H, CONH2, T(n)-R, or T(n)-Ar2, n may be zero or one, and G, XYZ, and Q are as described below. These compounds are inhibitors of protein kinase, particularly inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Grant
    Filed: February 13, 2004
    Date of Patent: January 30, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jeremy Green, Guy Bemis, Anne-Laure Grillot, Mark Ledeboer, Francesco G. Salituro, Edmund Harrington, Huai Gao, Christopher Baker, Jingrong Cao, Michael Hale
  • Publication number: 20070004762
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: February 2, 2006
    Publication date: January 4, 2007
    Inventors: Mark Ledeboer, Albert Pierce, Guy Bemis, Luc Farmer, Tiansheng Wang, David Messersmith, John Duffy, Francesco Salituro, Jian Wang